




UNITED STATES PATENT & TRADEMARK OFFICE

In re Application : ANA MARIA GARCIA COLLAZO, ET AL.
Serial No. : 10/593,927
Filed : September 21, 2006
For : NOVEL PHARMACEUTICAL COMPOSITIONS
COMPRISING AGONISTS OF THE THYROID
RECEPTOR
Examiner :
Attorney Docket : 102901-102
Group Art Unit :
Confirmation No. :
Customer No. : **27267**

CERTIFICATE OF MAILING

I hereby certify that this correspondence is being deposited with the United States Postal Service, First Class Mail, in an envelope addressed to: Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on 26 June 2007.

By 
Todd E. Garabedian, Ph.D.
Registration No. 39,197
Attorney for Applicants

INFORMATION DISCLOSURE STATEMENT

Mail Stop Amendment
Commissioner for Patents
P. O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

Pursuant to 37 C.F.R. §1.56, the Examiner is respectfully requested to consider the references cited on attached Form PTO-1449. A copy of each reference (if not previously submitted) is enclosed. It is respectfully requested that the information be expressly considered during the prosecution of this application, and that the reference(s) be made of record therein and appear among the "References Cited" on any patent to issue therefrom.

- [X] 1. This Information Disclosure Statement is being filed within three months of the U. S. filing date OR before the mailing date of a first Office Action on the merits. No certification or fee is required.

- [] 2. This Information Disclosure Statement is being filed more than three months after the U. S. filing date AND after the mailing date of the first Office Action on the merits, but before the mailing date of a Final Rejection or Notice of Allowance.
 - [] a. Each item of information contained on Form PTO-1449 filed herewith was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement. 37 C.F.R. §1.97(e)(1); and no fee is required under 37 C.F.R. §1.17(p).
 - [] b. No item of information cited on Form PTO-1449 filed herewith was cited in a communication from a foreign patent office in a counterpart foreign application or, to my knowledge after making reasonable inquiry, was known to any individual designated in 37 C.F.R. §1.56(c) more than three months prior to the filing of this Information Disclosure Statement. 37 C.F.R. §1.97(e)(2); and no fee is required under 37 C.F.R. §1.17(p).
- [] Please charge Deposit Account No. 23-1665 in the amount of \$180.00 in payment of the fee under 37 C.F.R. §1.17(p). Two additional copies of this Information Disclosure Statement are enclosed.
- [] A check in the amount of \$180.00 is attached hereto in payment of the fee under 37 C.F.R. §1.17(p).
- [] 3. This Information Disclosure Statement is being filed more than three months after the U.S. filing date and after the mailing date of a Final Rejection or Notice of Allowance, but before payment of the Issue Fee. It is hereby requested that the Information Disclosure Statement be considered.
 - [] a. Each item of information contained on Form PTO-1449 filed herewith was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement. 37 C.F.R. §1.97(e)(1).
 - [] b. No item of information cited on Form PTO-1449 filed herewith was cited in a communication from a foreign patent office in a counterpart foreign application or, to my knowledge after making reasonable inquiry, was known to any individual designated in 37 C.F.R. §1.56(c) more than three months prior to the filing of this Information Disclosure Statement. 37 C.F.R. §1.97(e)(2).

- [] Please charge Deposit Account No. 23-1665 in the amount of \$130.00 in payment of the fee under 37 C.F.R. §1.17(i)(1). Two additional copies of this Information Disclosure Statement are enclosed.
- [] A check in the amount of \$130.00 is attached hereto in payment of the fee under 37 C.F.R. §1.17(i)(1).

The undersigned represents that the closest art of which he is presently aware has been cited herein and understands that this statement shall not be construed as a representation that no better art exists or that a thorough patentability search has been made.

The undersigned further represents that the filing of this Information Disclosure Statement shall not be construed to be an admission that the information cited in the Statement is, or is considered to be, material to patentability as defined in 37 C.F.R. §1.56(b).

Respectfully submitted,

ANA MARIA GARCIA COLLAZO, ET AL.

Date: 26 June 2007

By: Todd E. Garabedian
Todd E. Garabedian, Ph.D.
Registration No. 39,197
Attorney for Applicants

WIGGIN AND DANA LLP
One Century Tower
New Haven, CT 06508-1832
Telephone : (203) 498-4400
Facsimile: (203) 782-2889



UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application : ANA MARIA GARCIA COLLAZO, ET AL.
Serial No. : 10/593,927
Filed : September 21, 2006
For : NOVEL PHARMACEUTICAL COMPOSITIONS
COMPRISING AGONISTS OF THE THYROID
RECEPTOR
Examiner :
Attorney Docket : 102901-102
Group Art Unit :
Confirmation No. :
Customer No. : **27267**

CERTIFICATE OF MAILING

I hereby certify that this correspondence is being deposited with the United States Postal Service, in an Express Mail envelope addressed to: Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on 26 June 2007.

By Todd E. Garabedian
Todd E. Garabedian, Ph.D.
Registration No. 39,197
Attorney for Applicants

INFORMATION DISCLOSURE LETTER

Mail Stop Amendment
Commissioner for Patents
P. O. Box 1450
Alexandria, VA 22313-1450

Sir:

The undersigned represents that the closest art of which he is presently aware has been cited herein and understands that this statement shall not be construed as a representation that no better art exists or that a thorough patentability search has been made.

The undersigned further represents that the filing of this Information Disclosure Statement shall not be construed to be an admission that the information cited in the Statement is, or is considered to be, material to patentability as defined in 37 C.F.R. § 1.56(b).

1. United States Patent No. 3,586,713 (BUU-HOI, NGUYEN PHUC, ET AL.) 22 June 1971 (1971-06-22).
2. United States Patent No. 3, 492,349 (DOYLE, FRANK PETER, ET AL.) 27 January 1970 (1970-01-27).
3. International Patent Application No. WO 01/36365 A2 (MALM, JOHAN, ET AL.) 25 May 2001 (2001-05-25).
4. International Patent Application No. WO 03/084915 A1 (RAHIMI-GHADIM, MAHMOUD, ET AL.) 16 October 2003 (2003-10-16).
5. International Patent Application No. WO 03/018515 A2 (MALM, JOHAN, ET AL.) 6 March 2003 (2003-03-06).
6. International Patent Application No. WO 02/092550 A1 (MALM, JOHAN, ET AL.) 21 November 2002 (2002-11-21).
7. International Patent Application No. WO 2005/092317 A1 (GARCIA COLLAZO, ANA MARIA, ET AL.) 6 October 2005 (2005-10-06).
8. International Patent Application No. WO 2005/051373 A2 (FUKATSU, KOHJI, ET AL.) 9 June 2005 (2005-06-09). This Patent discloses a 14273 receptor function regulating agent useful as a preventive/therapeutic agent for diabetes, hyperlipemia, etc. There is provided a 14273 receptor function regulating agent comprising a compound having a group capable of releasing an aromatic ring and a cation.
9. International Patent Application No. WO 03/094845 A2 (ZHANG, MINSHENG, ET AL.) 20 November 2003 (2003-11-20).
10. International Patent Application No. WO 03/059872 A1 (DIXON, JULIE, ET AL.) 24 July 2003 (2003-07-24).
11. International Patent Application No. WO 01/60784 A1 (FRIENDS, TODD JASON, ET AL.) 23 August 2001 (2001-08-23).
12. International Patent Application No. WO 97/28137 (ADAMS, ALAN D>, ET AL.) 7 August 1997 (1997-08-07).
13. International Application Publication No. WO 95/04049 (LEONARDI, AMEDEO, ET AL.) 9 February 1995 (1995-02-09).
14. European Patent Application No. EP 1 148 054 A1 (CHIANG, YUAN-CHING P.) 24 October 2001 (2001-10-24).

15. European Patent Specification No. EP 1 148 054 B1 (CHIANG, YUAN-CHING P.) 23 November 2005 (2005-11-23).
16. European Patent Application No. EP 0 257 828 A1 (TAKAHASHI, JUNYA, ET AL.) 2 March 1988 (1988-03-02).
17. European Patent Specification No. EP 0 257 828 B1 (TAKAHASHI, JUNYA, ET AL.) 27 December 1990 (1990-12-27).
18. United Kingdom Patent Application No. 2 028 820 A (YOSHIAKI, KOSUGE, ET AL.) 12 March 1980 (1980-03-12).
19. United Kingdom Patent Application No. 2 016 010 A (RYO, YOSHIDO, ET AL.) 19 September 1979 (1979-09-19).
20. A. DIBBO, ET AL., "*The Synthesis of Thyroxine and Related Compounds. Part XVII. The Preparation of Some Additional Compounds Related to Thyroxine*", JOURNAL OF THE CHEMICAL SOCIETY, Pages 2890-2902 (1961).
21. N. P. BUU-HOI, ET AL., "*Acides Arylacéthydroxamiques anti-inflammatoires et analgésiques*", CHIMIE THÉRAPEUTIQUE, No. 1, Pages 39-48 (October 24, 1966). This article discusses the synthesizing of certain acids to determine their biological properties, thereby obtaining certain compounds of interest by virtue of their pronounced anti-inflammatory, analgesic or spasmolytic properties.
22. A. P. BROWN, M. A., M.C.I.L., M.I.T.I. Affidavit attesting to the accuracy of an English translation of the title and abstract of the article listed in item 21 above.
23. P. D. LEESON, ET AL., "*Thyroid Hormone Analogues, Synthesis of 3'-Substituted 3,5-Diiodo-L-thyronines and Quantitative Structure – Activity Studies of in Vitro and in Vivo Thyromimetic Activities in Rat Liver and Heart*", JOURNAL OF MEDICAL CHEMISTRY, Vol. 31, No. 1, Pages 37-54 (1988).

Applicants submit that copies of the above-cited references are enclosed herewith.

If the Examiner has any questions or feels that a discussion with Applicants' representative would expedite prosecution, the Examiner is invited and encouraged to contact Applicants' undersigned representative at the telephone number listed below.

Respectfully submitted,

ANA MARIA GARCIA COLLAZO, ET AL.

Date: 26 June 2007

By: Todd E. Garabedian
Todd E. Garabedian, Ph.D.
Registration No. 39,197
Attorney for Applicants

WIGGIN AND DANA LLP
One Century Tower
P. O. Box 1832
New Haven, CT 06508-1832
Telephone: (203) 498-4400
Fax: (203) 782-2889

\16777\5\56293.1

FORM PTO-1449

INFORMATION DISCLOSURE STATEMENT BY APPLICANT		ATTY. DOCKET NO. 102901-102		SERIAL NO. 10/593,927		
PAGE 1 OF 2		APPLICANT: ANA MARIA GARCIA COLLAZO, ET AL.				
		FILING DATE: SEPTEMBER 21, 2006		GROUP:		
U.S. PATENT DOCUMENTS						
EXAMINER INITIAL*	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPR.
	3,586,713	06/22/1971	BUU-HOI, N. P., et al.	C07c	83/00	
	3,492,349	01/27/1970	DOYLE, F. P., et al.	C07c	97.00	
FOREIGN PATENT DOCUMENTS						
	DOCUMENT NO.	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION Yes No
	WO 01/36365 A2	05/25/2001	PCT	C07C	59/64	
	WO 03/084915 A1	10/16/2003	PCT	C07C	59/215	
	WO 2003/018515 A2	03/06/2003	PCT	C07C		
	WO 02/092550 A1	11/21/2002	PCT	C07C	229/36	
	WO 2005/092317 A1	10/06/2005	PCT	A61K	31/192	
	WO 2005/051373 A1	06/09/2005	PCT	A61K	31/192	X
	WO 03/094845 A2, A3	11/20/2003	PCT	A61K		
	WO 03/059872 A1	07/24/2003	PCT	C07C	317/32	
	WO 01/60784 A1	08/23/2001	PCT	C07C	235/74	
	WO 97/28137	08/07/1997	PCT	C07D	261/20	
	WO 95/04049	02/09/1995	PCT	C07D	298/08	
OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.)						
	A. DIBBO, ET AL., "The Synthesis of Thyroxine and Related Compounds. Part XVII. The Preparation of Some Additional Compounds Related to Thyroxine", JOURNAL OF THE CHEMICAL SOCIETY, Pages 2890-2902 (1961).					
	N. P. BUU-HOI, ET AL., "Acides Arylacéthydroxamiques anti-inflammatoryes et analgésiques", CHIMIE THÉRAPEUTIQUE, No. 1, Pages 39-48 (October 24, 1966). This article discusses the synthesizing of certain acids to determine their biological properties, thereby obtaining certain compounds of interest by virtue of their pronounced anti-inflammatory, analgesic or spasmolytic properties.					
	A. P. BROWN, M. A., M.C.I.L., M.I.T.I. Affidavit attesting to the accuracy of an English translation of the title and abstract of the article by N. P. Buu-Hoi, et al., listed immediately above.					
	P. D. LEESON, ET AL., "Thyroid Hormone Analogues, Synthesis of 3'-Substituted 33,5-Diiodo-L-thyronines and Quantitative Structure - Activity Studies of in Vitro and in Vivo Thyromimetic Activities in Rat Liver and Heart", JOURNAL OF MEDICAL CHEMISTRY, Vol. 31, No. 1, Pages 37-54 (1988).					
EXAMINER:			DATE CONSIDERED:			
<p>*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. \16777\5\56292.1</p>						

FORM PTO-1449



INFORMATION DISCLOSURE STATEMENT BY APPLICANT		U.S. PATENT & TRADEMARK OFFICE DOCKET NO. 102901-102		SERIAL NO. 10/593,927		
PAGE 2 OF 2		APPLICANT: ANA MARIA GARCIA COLLAZO, ET AL.				
		FILING DATE: SEPTEMBER 21, 2006		GROUP:		
U.S. PATENT DOCUMENTS						
EXAMINER INITIAL*	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	
FOREIGN PATENT DOCUMENTS						
	DOCUMENT NO.	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION Yes No
	EP 1 148 054 A1	10/24/2001	EP	C07D	271/06	
	EP 1 148 054 B1	11/23/2005	EP	C07D	271/06	
	EP 0257 828 A1	03/02/1988	EP	C07C	43/225	X
	EP 0 257 828 B1	12/27/1990	EP	C07C	43/225	X
	GB 2 028 820 A	03/12/1980	Great Britain	C07C	125/063	
	GB 2 016 010 A	09/19/1979	Great Britain	C07C	127/19	
OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.)						
EXAMINER:			DATE CONSIDERED:			
<p>*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.</p> <p>(16777)5 56292.1</p>						